GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » Cyclically Adjusted Price-to-FCF

Sonoma Pharmaceuticals (STU:O8Z3) Cyclically Adjusted Price-to-FCF : (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sonoma Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Sonoma Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.093/129.4194*129.4194
=-0.093

Current CPI (Dec. 2023) = 129.4194.

Sonoma Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -6.599 99.695 -8.567
201406 -5.438 100.560 -6.999
201409 -6.804 100.428 -8.768
201412 -4.759 99.070 -6.217
201503 -8.507 99.621 -11.052
201506 -7.226 100.684 -9.288
201509 -4.512 100.392 -5.817
201512 -7.060 99.792 -9.156
201603 -3.877 100.470 -4.994
201606 -4.567 101.688 -5.812
201609 -3.195 101.861 -4.059
201612 -3.232 101.863 -4.106
201703 -5.709 102.862 -7.183
201706 -8.939 103.349 -11.194
201709 -4.562 104.136 -5.670
201712 -3.766 104.011 -4.686
201803 -4.364 105.290 -5.364
201806 -3.812 106.317 -4.640
201809 -4.270 106.507 -5.189
201812 -2.166 105.998 -2.645
201903 -1.863 107.251 -2.248
201906 0.481 108.070 0.576
201909 -0.664 108.329 -0.793
201912 -0.509 108.420 -0.608
202003 -1.893 108.902 -2.250
202006 -1.129 108.767 -1.343
202009 -0.158 109.815 -0.186
202012 0.268 109.897 0.316
202103 -0.597 111.754 -0.691
202106 -0.505 114.631 -0.570
202109 -0.482 115.734 -0.539
202112 -0.094 117.630 -0.103
202203 -0.428 121.301 -0.457
202206 -0.475 125.017 -0.492
202209 -0.604 125.227 -0.624
202212 -0.115 125.222 -0.119
202303 -0.576 127.348 -0.585
202306 -0.043 128.729 -0.043
202309 -0.224 129.860 -0.223
202312 -0.093 129.419 -0.093

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sonoma Pharmaceuticals  (STU:O8Z3) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines